Short Interest in Eyenovia, Inc. (NASDAQ:EYEN) Drops By 41.4%

Eyenovia, Inc. (NASDAQ:EYEN) was the recipient of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 138,200 shares, a decrease of 41.4% from the February 28th total of 236,000 shares. Based on an average trading volume of 447,700 shares, the days-to-cover ratio is presently 0.3 days. Approximately 6.6% of the shares of the stock are sold short.

Eyenovia Trading Down 10.3 %

NASDAQ EYEN traded down $0.13 during trading hours on Friday, reaching $1.13. The company’s stock had a trading volume of 88,711 shares, compared to its average volume of 151,096. Eyenovia has a 52 week low of $1.13 and a 52 week high of $124.80. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a market cap of $1.57 million, a P/E ratio of -0.02 and a beta of 1.29. The firm has a fifty day simple moving average of $2.18 and a 200-day simple moving average of $16.35.

Hedge Funds Weigh In On Eyenovia

A hedge fund recently raised its stake in Eyenovia stock. Geode Capital Management LLC grew its holdings in shares of Eyenovia, Inc. (NASDAQ:EYEN) by 36.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 557,994 shares of the company’s stock after buying an additional 149,471 shares during the quarter. Geode Capital Management LLC owned 0.87% of Eyenovia worth $288,000 at the end of the most recent reporting period. Institutional investors own 25.84% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating and issued a $2.00 target price on shares of Eyenovia in a research report on Friday, March 21st.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.